Vaccine, pertussis


Concise Prescribing Info
Indications/Uses
Active immunisation against pertussis.
Dosage/Direction for Use
Adult : IM 11-64 yr: As combination product w/ diphtheria and tetanus toxoids: 0.5 mL as a single dose. Ensure that 5 yr have elapsed since the last dose of tetanus toxoid, diphtheria toxoid and/or pertussis containing vaccine.
Dosage Details
Intramuscular
Active immunisation against pertussis
Adult: 11-64 yr: As combination product with diphtheria and tetanus toxoids: 0.5 ml as a single dose, preferably into the deltoid muscles. Ensure that 5 yr should have elapsed since the last dose of tetanus toxoid, diphtheria toxoid and/or pertussis containing vaccine.
Child: As a combination product with diphtheria, tetanus, inactivated poliomyelitis and HIB conjugate vaccine: 3 doses of 0.5 ml each, given at 1 mth intervals. Booster dose may be given at 18 mth-6 yr of age prior to school entry (3 yr after primary course).
Contraindications
Hypersensitivity to active substances and/or neomycin, polymyxin or formaldehyde.
Special Precautions
Continue immunisation with acellular pertussis vaccine even during episodes of fever, hypotonic-hyporesponsive episodes, persistent crying or screaming or severe local reactions have occurred after a preceding dose. Children with personal or family history of convulsions or epilepsy. Children with a local or general reaction to a whole-cell pertussis vaccine should complete their immunisation with acellular pertussis vaccine. If a seizure associated with fever occurs within 72 hr of immunisation or a child experiences encephalopathy or encephalitis within 7 days of immunisation, defer further immunisation until the condition is stable if no underlying cause is found and the child has not recovered completely within 24 hr.
Adverse Reactions
Local reactions at inj site, fever and irritability, may start a few hrs after inj and last for 1 or 2 days, possibly with inflammation and lymphangitis. Rare neurological reactions e.g. convulsions and encephalopathy. Hypersensitivity reactions may occur and anaphylaxis has been reported rarely.
IM/Parenteral: C
Drug Interactions
Reduced immune response in patients who are also taking immunosuppressants.
Action
Description: Pertussis vaccine is used for active immunisation against pertussis.
Storage
Store at 2-8 °C, do not freeze and protect from light.
Disclaimer: This information is independently developed by MIMS based on Vaccine, pertussis from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in